MANHATTAN PHARMACEUTICALS INC

NEW YORK, NY · CIK 0001001316 · Biotech · Private

Pharmaceutical development and commercialization platform for drug candidates

manhattan.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$14M
2 Form D · Mar 2012
174 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,547,500
Private capital raisedForm D · SEC$11,091,426
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2477ImmunGene——
2478MABVAX THERAPEUTICS INC—$16M
2479INGENUITY SYSTEMS INC—$15M
2480MANHATTAN PHARMACEUTICALS INC—$14M
2481CORNERSTONE PHARMACEUTICALS INC—$13M
2482DMC Limited——
2483Curie Co. Inc.—$13M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Douglas AbelDirector
  • Neil HerskowitzDirector
  • NEIL HERSKOWITZDirector
  • Michael McGuinnessExecutive Officer
  • Timothy McInerneyDirector
  • Sean PowerExecutive Officer
  • SEAN POWERExecutive Officer
  • Richard SteinhartDirector
  • Michael WeissDirector · Executive Officer
  • MICHAEL WEISSDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.